Pharma dose CMOs face slow growth amidst challenging market conditions

The global shortage of generic drugs has worsened over the past year.

Drug pricing pressures, regulatory changes, and geopolitical tensions present challenges and opportunities for contract manufacturing organisations (CMOs), said GlobalData.

The report revealed that the pharmaceutical finished dose contract manufacturing sector experienced a slowdown in revenue growth over the past financial year.

Moreover, the global shortage of generic drugs has worsened over the past year, leaving patients without access to essential medications.

“CMOs with the capacity to make generics – including less technically innovative manufacturers – have an opportunity to help resolve these shortages and win business,” the report said.

Moreover, governments have begun stockpiling critical drugs, investing in domestic pharmaceutical manufacturing, and considering price increases for generics to incentivise production.